ReviewCell stress & chaperones2026
Hsp90: A means to an end.
Review in Cell stress & chaperones, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Urinary HSP90 as a non-invasive biomarker of active tubular injury in kidney transplant recipients: A multicenter prospective study.Cell stress & chaperones · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Hsp90 molecular chaperone is a key component of the protein homeostasis (proteostasis) system. Hsp90 likely serves as a gatekeeper in a cell's protein quality control decision tree since this chaperone is linked to nascent polypeptide folding, client maturation, metastable protein maintenance, and polypeptide degradation. Interestingly, how a client protein is directed through the decision process is unclear. Minimally, modifications to the amino-terminal ATP-binding domain of Hsp90 can favor client degradation. As this includes a common class of Hsp90 inhibitors that trigger the breakdown of clinically relevant factors, a better understanding of Hsp90's role in quality control is merited. Here, we explore how Hsp90 links to both polypeptide biogenesis and triage, the events that regulate the decision route, and how Hsp90's connections to proteolysis pathways are being exploited for the development of new therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.